Cancer Story Deep-Dive

Patient Savvy

Welcome to the Cancer Story Deep-Dive Podcast by Patient Savvy—a space where courage meets cutting-edge cancer care. Each episode, we share inspiring stories from patients and caregivers, breaking down complex cancer treatments and advances into relatable language. In the 1st season, we take a focused journey into the realm of precision medicine in lung cancer. We’ll explore each biomarker and its corresponding treatment, using real-life patient experiences to bring these discussions to life. Join us for more cancer information: https://patientsavvy.org/

Episodes

  1. 06/29/2025

    Ep 7 - TROP2 Antibody-Drug Conjugate

    This episode covers the basics of TROP2 antibody-drug conjugates (ADCs), a new and promising treatment for lung cancer. We explain how ADCs work differently from chemotherapy and immunotherapy by delivering powerful cancer-killing drugs directly to tumor cells with fewer side effects. The episode highlights TROP2 as a key target in lung cancer and discusses the latest research on TROP2 ADCs, including datopotamab deruxtecan. We review recent clinical trial results showing improved outcomes for some patients, current FDA review status, and what these advances could mean for patients and caregivers. The episode also touches on ongoing research, potential side effects, and the growing excitement and investment in ADC therapies for cancer. See More ⁠HERE⁠

    Ep 7 - TROP2 Antibody-Drug Conjugate

  2. 04/07/2025

    Ep 6 - MET-Amplification: Achieving Stable Condition in Extensive Metastatic NSCLC

    In this episode, we explore the groundbreaking impact of targeted therapy for MET amplification in non-small cell lung cancer (NSCLC), focusing on how it has transformed the treatment landscape for patients with advanced, metastatic disease. We’ll delve into the science behind MET amplification, explaining how targeting its overactive signaling can hinder tumor growth and potentially offer new hope for patients facing stage IV NSCLC.  By the end of this episode, our goal is to equip you with the knowledge to discuss targeted therapies with confidence, empowering you to make informed decisions with your healthcare team regarding the most appropriate treatment options for your individual needs. Cre: Patient Resource See More HERE

    Ep 6 - MET-Amplification: Achieving Stable Condition in Extensive Metastatic NSCLC

  3. 04/07/2025

    Ep 5 - RET-Fusion: 9 Years Beyond a 3% Survival Chance of Stage IV NSCLC

    In this episode, we dive into the transformative potential of targeted therapy for RET fusion-positive lung cancer, spotlighting how it has dramatically reshaped outcomes for a young patient with extensive metastatic NSCLC. We’ll break down the science behind the RET pathway, revealing how blocking its abnormal signals can stall tumor growth and even turn stage IV cancer into a more manageable condition. We’ll also address possible side effects, ensuring you gain a balanced perspective on these breakthrough medications. By the end of this episode, our goal is to empower you with the knowledge to discuss RET-targeted therapies more confidently with your healthcare team, helping you weigh their suitability and benefits for your specific situation Source: Cleveland Clinic See More ⁠HERE

    Ep 5 - RET-Fusion: 9 Years Beyond a 3% Survival Chance of Stage IV NSCLC

  4. 03/17/2025

    Ep 4 - PD-L1 immunotherapy: Unleashing Your Immune System Against Cancer

    In this episode, we delve into immunotherapy which offers a unique approach compared to targeted therapy. We'll explore how immunotherapy has dramatically shifted the prognosis for lung cancer patients, especially those with advanced disease Our discussion will break down the science behind the PD-1/PD-L1 pathway, explaining how blocking this interaction can reactivate your immune system to combat cancer and potentially provide long-term benefits. We’ll also address its possible side effects, ensuring you have a balanced perspective on the treatment. By the end of this episode, our goal is to empower you with the knowledge to confidently discuss PD-L1 immunotherapy with your healthcare team, including assessing its suitability and potential benefits for your specific case. Source: L’Hopital d’Ottawa See More HERE

    Ep 4 - PD-L1 immunotherapy: Unleashing Your Immune System Against Cancer

  5. 03/17/2025

    Ep 3 - ALK mutation: Keep cancer remain under control regardless of recurrence

    In this episode, we dive into ALK-targeted treatment and its profound impact on the cancer journey of a survivor with extensive metastases. We'll unravel the science behind ALK and illustrate how therapies aimed at this biomarker have revolutionized treatment strategies.  Notably, this approach highlights that targeted therapy remains a viable option even after progression or recurrence following chemotherapy and immunotherapy. Join us as we share an inspiring story of resilience, showcasing both the challenges and breakthroughs that define this remarkable journey. Source: City of hope

    Ep 3 - ALK mutation: Keep cancer remain under control regardless of recurrence

  6. 03/14/2025

    Ep 2 - ROS1 mutation: From extensive metastases to 3 years cancer free and counting

    In this episode, we explore ROS1-targeted treatment and its transformative impact on the cancer journey of a young survivor with extensive metastases. We'll break down the science behind ROS1—a biomarker present in just 1-2% of NSCLC cases—and show how targeting it has reshaped treatment strategies.  Join us as we share an inspiring story of resilience, highlighting both the challenges and breakthroughs in a cancer journey, and emphasizing the crucial role of genetic testing in personalized care. See More HERE Cre: Mass General Cancer Center

    Ep 2 - ROS1 mutation: From extensive metastases to 3 years cancer free and counting

  7. 03/14/2025

    Ep 1 - EGFR mutation: 25+ years beyond stage 4 NSCLC prognosis

    Welcome to the first episode of our season on precision medicine in lung cancer. Today, we're exploring a pivotal breakthrough from the late 1990s—EGFR-targeted therapy—and its revolutionary impact on stage 4 lung cancer care. In this episode, we highlight the inspiring story of Wells, a cancer survivor for over 25 years, whose life was transformed by this treatment. We’ll break down the science behind EGFR, demonstrating how targeting this biomarker has become a cornerstone in the management of metastatic NSCLC. Our aim is to empower you with the knowledge needed to engage confidently with your healthcare team as EGFR-targeted therapy continues to set the standard of care. Whether you're a patient, a caregiver, or simply curious about cancer treatment advances, we hope this episode offers an informative and inspiring start to our deep-dive series. See more HERE Cre: Go2 for Lung Cancer  #PatientSavvy

    Ep 1 - EGFR mutation: 25+ years beyond stage 4 NSCLC prognosis
  • 7 Episodes

About

Welcome to the Cancer Story Deep-Dive Podcast by Patient Savvy—a space where courage meets cutting-edge cancer care. Each episode, we share inspiring stories from patients and caregivers, breaking down complex cancer treatments and advances into relatable language. In the 1st season, we take a focused journey into the realm of precision medicine in lung cancer. We’ll explore each biomarker and its corresponding treatment, using real-life patient experiences to bring these discussions to life. Join us for more cancer information: https://patientsavvy.org/

Information

  • Creator
    Patient Savvy
  • Years Active
    2025
  • Episodes
    7
  • Rating
    Clean
  • Copyright
    © Patient Savvy
  • Show Website
    Cancer Story Deep-Dive